申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2105435A1
公开(公告)日:2009-09-30
A hydrazone derivative of formula [I]:
wherein Ring A is aryl or heteroaryl, Ring T is heteroaryl or heterocycle, R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl, etc., R3 and R4 combine each other together with the adjacent nitrogen atom to form substituted or unsubstituted heterocycle, R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl, etc., and R6 is hydrogen atom, etc.; or a pharmaceutically acceptable salt thereof is useful as a gluokinase activation agent.
式 [I] 的腙衍生物:
其中环 A 为芳基或杂芳基,环 T 为杂芳基或杂环,R1 和 R2 独立地为氢原子、卤素原子、环烷基磺酰基等,R3 和 R4 与相邻的氮原子相互结合形成取代或未取代的杂环,R5 为氢原子、卤素原子、氰基、硝基、四唑基等,R6 为氢原子等;或其药学上可接受的盐可用作糖激酶活化剂。